Biogenysis Inc. & Khalpey AI Lab join forces to unlock secrets of Alzheimer’s Disease with Artificial Intelligence!

Enzolytics’ subsidiary Biogenysis, Inc. (BGEN) has forged an exciting new partnership with Khalpey AI Lab to discover biomarkers for early-onset Alzheimer’s Disease. Through this collaboration, BGEN and Khalpey will support the development of more effective treatments for this debilitating condition and, ultimately, move us ever closer to conquering this ravaging disorder.

Alzheimer’s disease is a devastating reality for millions of people of all ages – with over 5.2 million affected in the US alone. Yet there is hope in the form of advanced AI technology. By harnessing the power of high-throughput technology and analyzing vast biological data, AI offers powerful new insights into the causes and effects of the disease – providing valuable tools for the diagnosis, treatment, and prediction of Alzheimer’s. Here’s to a brighter future for our loved ones!

The collaboration between researchers is set to revolutionize the fight against Alzheimer’s disease, with the goal of identifying early biomarkers and developing new therapeutic treatments to help delay or even prevent the progression of the disease. By making breakthroughs in this area, the hope is to provide those facing early onset Alzheimer’s with a better quality of life.

Dr. Zain Khalpey, the director of the AI Lab, is determined to make the future of AI an attainable reality through advancing applied AI models in healthcare to the patient’s bedside. Through innovative technology and partnerships, the AI Lab’s research is helping create a brighter and more intelligent tomorrow by elevating patient data collection and analysis to revolutionary heights.

With the integration of our tools into the Biogenysis AI platform, healthcare professionals now have the power to make more informed decisions and even anticipate and prevent potential adverse events before they arise. We are proud to take the helm of medical technology and look forward to a smarter tomorrow!

Dr. Gaurav Chandra, CEO of Biogenysis, Inc., is thrilled to announce the collaboration with Dr. Zain Khalpey’s AI Lab – a powerful partnership that promises to revolutionize drug discovery and bring personalized, proactive healthcare closer than ever before.

Through the application of AI, Biogenysis seeks to identify early biomarkers for Alzheimer’s Disease and ultimately discover new therapeutic targets for its treatment. As part of this initiative, the AI model will take into account genetics, nutrition, and the microbiome, while also having the potential to be applied to other chronic diseases. With this exciting development, Biogenysis firmly plants its flag in the frontiers of healthcare, hoping to deliver effective medical care for all.

Enzolytics, Inc. Overview

Enzolytics, Inc. is on the forefront of drug development, utilizing revolutionary technology to create fully human monoclonal antibodies to combat the spread of infectious diseases.

Currently, the company is utilizing its innovative technology to produce therapies that target the alarming CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus, and expanding its reach to include additional viral targets such as HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).

Moreover, the company is dedicated to creating monoclonal antibodies to target animal viruses, giving rise to a revolutionary new era in the fight against contagious diseases.

The Company is furthering its groundbreaking research with ITV-1 (Immune Therapeutic Vaccine-1), a patented and clinically-tested composition featuring Inactivated Pepsin Fraction (IPF). Backed by the prestigious U.S. Patent Nos. 8,066,982 and 7,479,538, ITV-1 has been proven a successful treatment for HIV/AIDS and was even able to modulate the immune system in preliminary studies. So far, studies have already demonstrated its tremendous potential.

Leave a Comment